How JAK Inhibitors Revolutionized Dermatology Care
Apr 19, 2022, 09:15 PM
Last summer, Derm Discussions host Brad Glick, DO, invited Brett King, MD, PhD, Yale School of Medicine, to the program to discuss an emerging class of dermatology therapy known as Janus kinase (JAK) inhibitors.
At the time, small molecule drugs such as upadacitinib (Rinvoq) were approved for the treatment of conditions like rheumatoid arthritis and ulcerative colitis.
Since then, updacacitinib and abrocitinib (Cibinqo) have been approved for use in patients with atopic dermatitis, a skin condition that affects up to 7.3% of adults in the United States alone.
Janus kinase inhibitors modulate the activity of multiple cytokine drivers of atopic dermatitis, and are supported by a variety of positive clinical trial results.
Dr. Glick welcomed Dr. King back to Derm Discussions to provide insight into the role JAK inhibitors play in the ever-growing armamentarium against atopic dermatitis.
At the time, small molecule drugs such as upadacitinib (Rinvoq) were approved for the treatment of conditions like rheumatoid arthritis and ulcerative colitis.
Since then, updacacitinib and abrocitinib (Cibinqo) have been approved for use in patients with atopic dermatitis, a skin condition that affects up to 7.3% of adults in the United States alone.
Janus kinase inhibitors modulate the activity of multiple cytokine drivers of atopic dermatitis, and are supported by a variety of positive clinical trial results.
Dr. Glick welcomed Dr. King back to Derm Discussions to provide insight into the role JAK inhibitors play in the ever-growing armamentarium against atopic dermatitis.